Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sonia Vallet

Showing results (51-60 of 75) with videos related to

Pageof 8
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2003
PCR-detectable nonneoplastic Bcl-2/IgH rearrangements are common in normal subjects and cancer patients at diagnosis but rare in subjects treated with chemotherapyMarco Ladetto, Daniela Drandi, Mara Compagno, et al.
British Journal of Haematology|April 10, 2008
p38 mitogen-activated protein kinase inhibitor LY2228820 enhances bortezomib-induced cytotoxicity and inhibits osteoclastogenesis in multiple myeloma; therapeutic implicationsKenji Ishitsuka, Teru Hideshima, Paola Neri, et al.
Experimental Hematology|December 13, 2006
Cells carrying nonlymphoma-associated bcl-2/IgH rearrangements (NLABR) are phenotypically related to follicular lymphoma and can establish as long-term persisting clonal populationsMarco Ladetto, Barbara Mantoan, Federica De Marco, et al.
Blood|August 24, 2007
MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclastsSonia Vallet, Noopur Raje, Kenji Ishitsuka, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 16, 2024
Editor's Note: Targeting Akt and Heat Shock Protein 90 Produces Synergistic Multiple Myeloma Cell Cytotoxicity in the Bone Marrow MicroenvironmentAlissa Huston, Xavier Leleu, Xiaoying Jia, et al.
Cancers|March 11, 2023
Health-Related Quality of Life as Assessed by the EQ-5D-5L Predicts Outcomes of Patients Treated with Azacitidine-A Prospective Cohort Study by the AGMTLisa Pleyer, Sonja Heibl, Christoph Tinchon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2008
Targeting Akt and heat shock protein 90 produces synergistic multiple myeloma cell cytotoxicity in the bone marrow microenvironmentAlissa Huston, Xavier Leleu, Xiaoying Jia, et al.
Leukemia|September 7, 2021
Publisher Correction: JunB is a key regulator of multiple myeloma bone marrow angiogenesisFengjuan Fan, Stefano Malvestiti, Sonia Vallet, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 11, 2009
The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivoHiroshi Ikeda, Teru Hideshima, Mariateresa Fulciniti, et al.
Leukemia|May 19, 2021
JunB is a key regulator of multiple myeloma bone marrow angiogenesisFengjuan Fan, Stefano Malvestiti, Sonia Vallet, et al.
Pageof 8

Showing results (51-60 of 75) with videos related to

Sort By:
Pageof 8
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2003
PCR-detectable nonneoplastic Bcl-2/IgH rearrangements are common in normal subjects and cancer patients at diagnosis but rare in subjects treated with chemotherapyMarco Ladetto, Daniela Drandi, Mara Compagno, et al.
British Journal of Haematology|April 10, 2008
p38 mitogen-activated protein kinase inhibitor LY2228820 enhances bortezomib-induced cytotoxicity and inhibits osteoclastogenesis in multiple myeloma; therapeutic implicationsKenji Ishitsuka, Teru Hideshima, Paola Neri, et al.
Experimental Hematology|December 13, 2006
Cells carrying nonlymphoma-associated bcl-2/IgH rearrangements (NLABR) are phenotypically related to follicular lymphoma and can establish as long-term persisting clonal populationsMarco Ladetto, Barbara Mantoan, Federica De Marco, et al.
Blood|August 24, 2007
MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclastsSonia Vallet, Noopur Raje, Kenji Ishitsuka, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 16, 2024
Editor's Note: Targeting Akt and Heat Shock Protein 90 Produces Synergistic Multiple Myeloma Cell Cytotoxicity in the Bone Marrow MicroenvironmentAlissa Huston, Xavier Leleu, Xiaoying Jia, et al.
Cancers|March 11, 2023
Health-Related Quality of Life as Assessed by the EQ-5D-5L Predicts Outcomes of Patients Treated with Azacitidine-A Prospective Cohort Study by the AGMTLisa Pleyer, Sonja Heibl, Christoph Tinchon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2008
Targeting Akt and heat shock protein 90 produces synergistic multiple myeloma cell cytotoxicity in the bone marrow microenvironmentAlissa Huston, Xavier Leleu, Xiaoying Jia, et al.
Leukemia|September 7, 2021
Publisher Correction: JunB is a key regulator of multiple myeloma bone marrow angiogenesisFengjuan Fan, Stefano Malvestiti, Sonia Vallet, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 11, 2009
The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivoHiroshi Ikeda, Teru Hideshima, Mariateresa Fulciniti, et al.
Leukemia|May 19, 2021
JunB is a key regulator of multiple myeloma bone marrow angiogenesisFengjuan Fan, Stefano Malvestiti, Sonia Vallet, et al.
Pageof 8